MARRONE BIO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marrone Bio Innovations, Inc. - MBII
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marrone Bio Innovations, Inc. (NasdaqCM: MBII) to Bioceres Crop Solutions Corp. (NasdaqGS: BIOX). Under the terms of the proposed transaction, shareholders of Marrone will receive only 0.088 shares of Bioceres for each share of Marrone that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-mbii/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
- 04/27/2022
|
Marrone Bio Innovations, Inc. (MBII) Reports Q4 Loss, Tops Revenue Estimates
- Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0% and 3.85%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/28/2022
|
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2021 Results - Earnings Call Transcript
- Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2021 Results - Earnings Call Transcript
- 03/28/2022
|
Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results
- RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include:
- 03/28/2022
|
Marrone Bio Expands Biological Seed Treatment Collaboration for Row Crops
- Company poised for continued growth in a $6+ billion market¹ Company poised for continued growth in a $6+ billion market¹
- 03/24/2022
|
Best Penny Stocks To Buy? 4 Agriculture & Farmings Stocks To Watch
- Farming & Agriculture Penny Stocks To Watch Right Now. The post Best Penny Stocks To Buy?
- 03/22/2022
|
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Marrone Bio Innovations, Inc. Merger
- Wilmington, Delaware--(Newsfile Corp. - March 21, 2022) - Rigrodsky Law, P.A. is investigating Marrone Bio Innovations, Inc. ("Marrone") (NASDAQ: MBII) regarding possible breaches of fiduciary duties and other violations of law related to Marrone's agreement to be acquired by Bioceres Crop Solutions Corp. ("Bioceres") (NASDAQ: BIOX). Under the terms of the agreement, Marrone's shareholders will receive 0.088 shares of Bioceres common stock for each share of Marrone common stock they own.To learn more about this...
- 03/21/2022
|
MARRONE BIO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marrone Bio Innovations, Inc. - MBII
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marrone Bio Innovations, Inc. (NasdaqCM: MBII) to Bioceres Crop Solutions Corp. (NasdaqGS: BIOX). Under the terms of the proposed transaction, shareholders of Marrone will receive only 0.088 shares of Bioceres for each share of Marrone that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-mbii/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
- 03/18/2022
|
Why Is Marrone Bio Innovations (MBII) Stock Up Today?
- Today, a big merger announcement has prompted investors to pile into Marrone Bio Innovations and MBII stock, as this stock surges 50%. The post Why Is Marrone Bio Innovations (MBII) Stock Up Today?
- 03/17/2022
|
Marrone Bio (MBII) Stock Alert: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Marrone Bio Innovations, Inc. Is Fair to Shareholders
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Marrone Bio Innovations, Inc. (NASDAQ: MBII) to Bioceres Crop Solutions Corp. is fair to Marrone Bio shareholders. Under the terms of the proposed transaction, each share of Marrone Bio common stock will be exchanged at closing for ordinary shares of Bioceres at a fixed ratio of 0.088. Halper Sadeh encourages Marrone Bio shareholders to click here to learn more about their legal
- 03/16/2022
|
Bioceres Crop Solutions and Marrone Bio Announce Merger Agreement
- ROSARIO, Argentina & RALEIGH, N.C.--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (Bioceres) and Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI) announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. Under the terms of the transaction, which has been unanimously approved by the Board of Directors of both companies, each share of MBI common stock will be exchanged at closing for ordinary shares of Bioceres at a fixed ratio of 0.088, representing a value of approximately $236 million, based on the Bioceres and MBI share prices at market close on March 15, 2022 and the number of current outstanding MBI shares. This transaction will combine Bioceres’ expertise in bionutrition and seed care products with MBI’s leadership in the development of biological crop protection and plant health solutions, creating a global leader in the development and commercialization of sustainable agricultural solutions. The companies together operate in 46 countries with approximately 640 employees, including two wholly owned manufacturing facilities and research and development (R&D) facilities located in Davis, California, and Rosario, Argentina. “We are very excited about the value creation that will result from this combination for customers, employees and investors,” said Bioceres Chief Executive Officer Federico Trucco. “By combining our current commercialized products and pipelines, we will be in a position to serve all major agriculture input categories with low environmental impact, highly efficacious, biological based solutions.” Trucco added, “MBI’s commercial footprint in North America and Europe will strongly complement our existing efforts in these geographies, while Bioceres’ leadership in Latin America will provide an excellent channel for MBI’s portfolio in these important row-crop markets. Together, we will create a winning platform in one of the most dynamic segments of agriculture.” “Our merger has the potential to accelerate global reach, broaden our product offerings and expand our R&D programs,” said Kevin Helash, Chief Executive Officer of Marrone Bio. “Consumer and grower demand is accelerating for agricultural products that help produce safe, affordable food in a sustainable manner. We will be able to further serve that market opportunity and provide our distribution partners and our growers with greater returns on investment.” Helash noted that the merger is anticipated to generate $8 million in annual cost synergies, the majority of which relate to the elimination of duplicative public company expenses and consulting fees. “MBI and Bioceres have a shared culture of innovation and entrepreneurial spirit. With complementary R&D capabilities, the combination unlocks many additional possibilities for further groundbreaking commercial solutions,” Helash concluded. “Bioceres has a proven track record in successfully integrating and scaling up businesses that have cultures focused on the commercialization of innovation. Since we integrated Rizobacter just over five years ago, revenue almost tripled and margins have expanded, driving ~4x increase in EBITDA. Rizobacter had the team, the products, the industrial capabilities and strong customer relationships needed to materialize growth, and we partnered with their leadership to unlock the opportunity,” said Enrique Lopez Lecube, Bioceres’ CFO. “Concurrent with Rizobacter’s acquisition, Bioceres negotiated a $45 million long-term loan, today fully repaid, that brought in the financial resources to execute on our ambitious plans. Similarly, today we are announcing that in connection with the merger, we have agreed to terms for up to $45 million in long-term committed capital in the form of a convertible loan. In addition to each company’s existing cash position, we estimate that pro forma cash will be around $100 million. Finally, we are also announcing the conversion to equity of 75% of the 2023 convertible loan, with the other 25% restructured into a new 4-year loan,” added Lopez Lecube. “We are excited that the scale created by this combination with Bioceres can accelerate and expand the commercialization of Marrone’s existing products. The combined companies will have the quality, experience and depth of management as well as the financial resources to realize the full potential of Marrone’s pipeline,” said Dwight Anderson, Managing Partner at Ospraie Ag Science LLC, the largest shareholder of MBI. The combined company will have a diverse customer base, product portfolio and geographic reach across a wide range of crops, positioned to serve the massive market opportunity emerging from the bio-reduction and replacement of chemical ag inputs. Key products in the combined companies’ R&D pipelines include Bioceres’ HB4 drought tolerance program in wheat and soybeans and MBI’s breakthrough research in bioherbicides. Additionally, MBI recently submitted regulatory packages for its novel bioinsecticide/bionematicide products MBI-306 and MBI-206 to the U.S. Environmental Protection Agency and Brazilian authorities for approval, respectively. Transaction Details The transaction is expected to close in the third quarter of calendar 2022, subject to the approval of MBI shareholders, regulatory clearance and other customary closing conditions. Shareholders representing approximately 49% of MBI’s outstanding shares of common stock have entered into customary transaction support agreements, agreeing to vote their shares in favor of the merger agreement and transactions contemplated thereby. Upon close, MBI shareholders will own approximately 16 million shares of Bioceres, with at least two individuals designated by MBI to be appointed to Bioceres’ board of directors. Linklaters LLP is serving as legal counsel to Bioceres. Roth Capital Partners is serving as financial advisor to MBI, and Morrison & Foerster LLP is serving as legal counsel to MBI. Bioceres Financing And Capitalization Update In connection with the transaction, Bioceres has agreed to terms for a capital commitment with a principal amount between $37.5 million and $45 million in the form of a convertible loan. The loan will mature four years after closing and accrue interest at an annual rate of 9%, of which 5% will be payable in cash and 4% in-kind. At any time up to maturity the lenders will have the option to convert the loan into common shares of Bioceres at a strike price of $18 per share. Bioceres will have the option for a voluntary prepayment beginning 30 months after the date on which the loan has been effected. Bioceres has also entered into an agreement with holders of a convertible note with an outstanding principal amount of $49.1 million that matures in March 2023. Under such agreement, and pursuant to the terms of the convertible note, the holders of the convertible note have committed to convert 75% of the outstanding principal amount into shares of common stock of Bioceres. The remaining 25% of the principal amount outstanding will be rolled into a new loan facility with a maturity of 4 years and no rights to convert into equity. Under the proposed terms, the closing of the conversion of the existing convertible notes and closing of the related new term loan are expected to occur within six weeks, and the closing of the new convertible loan is conditioned on, and will occur simultaneously with the closing of the transaction. The terms of the conversion, new term loan and new convertible loan described above are subject to negotiation and execution of customary definitive documentation. Joint Conference Call Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube and Head of Investor Relations Rodrigo Krause, with MBI Chief Executive Officer Kevin Helash, will host a conference call to discuss the announcement, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of each company’s website here, for Bioceres, and here, for MBI. To access the call, please use the following information: Date: Thursday, March 17, 2022 Time: 8:30 a.m. EST, 5:30 a.m. PST Toll Free dial-in number: 1-844-200-6205 Toll/International dial-in number: 1-929-526-1599 Conference ID: 811982 Webcast: Click here Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have difficulty connecting with the conference call, please contact MZ Group at +1 (949) 491-8235. The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website here. A replay of the call will be available through March 24, 2022 following the conference. Toll Free Replay Number: 1-866-813-9403 International Replay Number: +44 204 525 0658 Replay ID: 962243 About Bioceres Crop Solutions Corp. Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4® program, the Company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit here. About Marrone Bio Innovations Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented agricultural company leading the movement to environmentally sustainable farming practices through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. The portfolio of 18 products helps customers operate more sustainably while increasing their return on investment. The company’s commercial products are sold globally and supported by a robust portfolio of more than 500 issued and pending patents. End markets include row crops; fruits and vegetables; trees, nuts and vines; and greenhouse production. Marrone Bio’s research and development program uses proprietary technologies to isolate and screen naturally occurring microorganisms and plant extracts to create new, environmentally sound solutions in agriculture. For more information, visit here. Forward-Looking Statements This communication contains certain “forward-looking” statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, concerning Bioceres, MBI and the proposed transaction between Bioceres and MBI. All statements other than statements of fact, including information concerning future results, are forward-looking statements. These forward-looking statements are generally identified by the words “anticipate,” “believe,” “estimate,” “expect,” “seek,” “intend,” “may,” “could” or similar expressions. Such forward-looking statements include, but are not limited to, statements about the benefits of the proposed transaction, including anticipated future financial and operating results, synergies, accretion and growth rates, Bioceres’, MBI’s and the combined company’s plans, objectives, expectations and intentions, and the expected timing of completion of the proposed transactions, including the acquisition of MBI and the financing transactions of Bioceres. There are several factors which could cause actual plans and results to differ materially from those expressed or implied in forward-looking statements. Such factors include, but are not limited to, the failure to obtain, or delays in obtaining, required regulatory approvals, and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the proposed transaction, or the failure to satisfy any of the other conditions to the proposed transaction on a timely basis or at all; the occurrence of events that may give rise to a right of one or both of the parties to terminate the business combination agreement; adverse effects on the market price of Bioceres’ or MBI’s common stock and on Bioceres’ or MBI’s operating results because of a failure to complete the proposed transaction in the anticipated timeframe or at all; the ability of Bioceres, MBI and the combined company to make payments on debt or to repay existing or future indebtedness when due or to comply with the covenants contained therein; adverse changes in the ratings of Bioceres’ debt securities or adverse conditions in the credit markets; negative effects of the announcement, pendency or consummation of the transaction on the market price of Bioceres’ or MBI’s common stock and on Bioceres’ or MBI’s operating results, including as a result of changes in key customer, supplier, employee or other business relationships; significant transaction costs, including financing costs, and unknown liabilities; failure to realize the expected benefits and synergies of the proposed transaction in the expected timeframes or at all; costs or difficulties related to the integration of MBI’s technology and operations into Bioceres; the risk of litigation or regulatory actions; the inability of Bioceres, MBI or the combined company to retain and hire key personnel; the risk that certain contractual restrictions contained in the business combination agreement during the pendency of the proposed transaction could adversely affect Bioceres’ or MBI’s ability to pursue business opportunities or strategic transactions; effects of changes in the regulatory environment in which Bioceres and MBI operate; changes in global, political, economic, business, competitive and market conditions; changes in tax and other laws and regulations; and other risks and uncertainties detailed in Bioceres’ Annual Report on Form 20-F for the fiscal year ended June 30, 2021, including in the sections thereof captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements,” as well as in its subsequent reports on Form 6-K, all of which are filed with the SEC and available at www.sec.gov and www.biocerescrops.com, and in MBI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Special Note Regarding Forward-Looking Statements and Trade Names,” as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.marronebio.com. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause actual results and the timing of events to differ materially from those expressed in or implied by such forward-looking statements. Given these risks and uncertainties, persons reading this communication are cautioned not to place undue reliance on such forward-looking statements. Bioceres and MBI assume no obligation to update or revise the information contained in this communication (whether as a result of new information, future events, changes in its expectations, other circumstances that exist after the date as of which the forward-looking statements were made or otherwise), except as required by applicable law. Important Additional Information In connection with the proposed transaction, Bioceres Crop Solutions Corp. (“Bioceres”) will file a registration statement on Form F-4 (the “registration statement”) with the Securities and Exchange Commission (“SEC”), which will contain a proxy statement of Marrone Bio Innovations, Inc. (“MBI”), that also constitutes a prospectus of Bioceres (the “proxy statement/prospectus”), and each party will file other documents regarding the proposed transaction with the SEC from time to time. Investors and security holders are urged to read the proxy statement/prospectus, as well as any amendments or supplements to those documents and other relevant documents filed with the sec when they become available because they will contain important information. When final, a definitive copy of the proxy statement/prospectus will be sent to MBI stockholders. Investors and security holders will be able to obtain the registration statement and the proxy statement/prospectus free of charge from the SEC’s website or from Bioceres or MBI. The documents filed by Bioceres with the SEC may be obtained free of charge at Bioceres’ website, at www.biocerescrops.com, or at the SEC’s website, at www.sec.gov. These documents may also be obtained free of charge from Bioceres by requesting them by mail at Bioceres Crop Solutions Corp., Investor Relations, Ocampo 210 bis, Predio CCT, Rosario Province of Santa Fe, Argentina. The documents filed by MBI with the SEC may be obtained free of charge at MBI’s website, at www.marronebio.com, or at the SEC’s website, at www.sec.gov. These documents may also be obtained free of charge from MBI by requesting them by mail at Marrone Bio Innovations, Inc., Investor Relations, 7780-420 Briar Creek Parkway, Raleigh, NC 27617, or by telephone at (530) 750-2800. Participants in the Solicitation Bioceres and MBI and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of consents in respect of the proposed transaction. Information about Bioceres’ directors and executive officers is available in Bioceres’ Annual Report on Form 20-F, filed with the SEC on October 29, 2021. Information about MBI’s directors and executive officers is available in MBI’s proxy statement dated April 26, 2021, for its 2021 Annual Meeting of Stockholders, and MBI’s Current Reports on Form 8-K, filed with the SEC on August 30, 2021 and February 22, 2022. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the registration statement, the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Bioceres or MBI using the sources as indicated above. No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
- 03/16/2022
|
Marrone Bio Innovations to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28 at 4:30 p.m. Eastern Time
- RALEIGH, N.C., March 08, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the fourth quarter and full year ended December 31, 2021, after market close on Monday, March 28, 2022.
- 03/08/2022
|
Marrone (MBII) Expands the Existing Inventory Line of Credit
- Marrone's (MBII) increase in the line of credit for inventory provides it with greater flexibility to support its commercial expansion in the future.
- 01/10/2022
|
Switching From Israel Chemicals To Mosaic
- Switching From Israel Chemicals To Mosaic
- 11/25/2021
|
7 Penny Stocks to Book Profits on Before 2022
- Penny stocks can turn a quick profit. These 7 picks are designed to do so before the end of this year and cover multiple sectors.
- 11/16/2021
|
Marrone Bio (MBII) Q3 Earnings In Line, Revenues Lag Estimates
- Marrone Bio's (MBII) third-quarter revenues were driven by strategic focus on global expansion in the major row crops.
- 11/15/2021
|
Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q3 2021 Results - Earnings Call Transcript
- Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Marrone Bio Innovations, Inc. (MBII) Reports Q3 Loss, Misses Revenue Estimates
- Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0.00% and -8.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2021
|
Marrone Bio Prepares to Submit Registration for Next-Generation Crop Protection Product in North America
- Company Also Looks to Expand Footprint in South America with Regulatory Submission of Bionematicide Seed Treatment, MBI-206, in Brazil Company Also Looks to Expand Footprint in South America with Regulatory Submission of Bionematicide Seed Treatment, MBI-206, in Brazil
- 09/09/2021
|
Marrone (MBII) & Terramera Partner to Boost Crop Protection
- Marrone (MBII) and Terramera are collaborating to bring technological and biological know-how to the market to enhance crop protection and create sustainable agricultural technologies.
- 08/19/2021
|
Marrone Bio (MBII) Q2 Earnings and Revenues Miss Estimates
- Marrone Bio's (MBII) Q2 revenues were affected by severe drought in the western United States that led to reduced demand for insecticides and fungicides.
- 08/18/2021
|
Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q2 2021 Results - Earnings Call Transcript
- Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q2 2021 Results - Earnings Call Transcript
- 08/16/2021
|
Marrone Bio Innovations, Inc. (MBII) Reports Q2 Loss, Lags Revenue Estimates
- Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -100.00% and -28.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/16/2021
|
Marrone Bio Innovations: Q2 Earnings Insights
- Shares of Marrone Bio Innovations (NASDAQ:MBII) fell 4.8% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.02), which missed the estimate of ($0.01).
- 08/16/2021
|
Marrone Bio Innovations, Inc. Reports Second-Quarter 2021 Financial Results
- DAVIS, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the second quarter ended June 30, 2021. Key results include:
- 08/16/2021
|
Marrone Bio and partner Rizobacter expand strategic alliance to supply Rizonema seed treatment in Brazil
- Marrone Bio Innovations Inc (NASDAQ:MBII) (FRA:0MB) and partner Rizobacter have announced that Rizonema, a biological seed treatment for nematodes and soil-dwelling insects, will be offered for use in row crops in Brazil, through an expanded distribution agreement. In a statement, Marrone Bio said multiple regulatory trials in Brazil have proven the efficacy of Rizonema on key nematode species in soybeans and corn.
- 07/12/2021
|
Marrone Bio leading the charge toward more environmentally-conscious effective pest management for farmers
- Marrone's products are made from naturally-occurring substances like bacteria or plant extracts Biopesticides used in conjunction with chemical ones gives growers more control over pests The biopesticide industry is projected to more than double to $6.4 billion by 2023 What Marrone Bio does: Marrone Bio Innovations Inc (NASDAQ:MBII) is leading the charge toward more environmentally-conscious effective pest management for farmers with its unique line of biological pesticides. Its products are made from naturally occurring substances such as microbes, bacteria, plant extracts, fatty acids or pheromones, and it is currently the only publicly traded biopesticide company on the US market.
- 06/05/2021
|
Marrone Bio strikes partnership with ATP Nutrition to distribute Stargus Biofungicide on Canadian broad-acre crops
- Marrone Bio Innovations Inc (NASDAQ: MBII) has entered into a partnership with ATP Nutrition of Manitoba to distribute Stargus Biofungicide on Canadian broad-acre crops such as canola, dry beans, peas, soybeans, and sunflower. The company said these products represent more than 30 million acres in Canada where the biocontrol market is estimated to be growing at a 12-15% compound annual growth rate.
- 06/03/2021
|
Marrone Bio Innovations Partners with ATP Nutrition to Distribute Stargus® Biofungicide in Canada
- Agreement Marks Expansion into the Broad Acre Crops Market Agreement Marks Expansion into the Broad Acre Crops Market
- 06/03/2021
|
Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q1 2021 Results - Earnings Call Transcript
- Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Misses Revenue Estimates
- Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0.00% and -0.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/13/2021
|
Marrone Bio sees 1Q revenue grow 14% on improved balance sheet amid strong biological crop protection sales
- Marrone Bio Innovations Inc (NASDAQ) reported its 11th consecutive growth quarter with revenues increasing 14% year-over-year to $11 million. The Davis, California-based group attributed the revenue growth to “further market penetration” for its biological crop protection products, particularly driven by its Venerate, Grandevo, and Regalia brands.
- 05/13/2021
|
Marrone Bio Innovations Issues Shareholder Letter
- DAVIS, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released an update letter to shareholders from Chief Executive Officer Kevin Helash.
- 05/13/2021
|
Wall Street mixed at midday despite better than expected jobs data
- 12:20pm: Pharmaceutical stocks fall The Dow was up 162 points, 0.5%, to 34,393 at midday. The Nasdaq was ticked down 7 points to 13,576, and the S&P 500 picked up 12 points, 0.3%, to 4,180.
- 05/06/2021
|
Marrone Bio says its BIOSt Nematicide seed treatment product achieved outstanding climate impact score of 9.8 out of 10
- Marrone Bio Innovations Inc (NASDAQ:MBII) has announced that its flagship BIOSt Nematicide seed treatment product achieved an outstanding climate impact score of 9.8 out of 10. The company said the Climate Impact Study showed that BIOSt Nematicide reduced greenhouse gas (GHG) emissions by 85% in soybeans and 87% in corn compared with conventional pesticides.
- 05/06/2021
|
BIOSt® Nematicide Seed Treatment Reduces Greenhouse Gas Emissions in Soybeans and Corn by 85%+ Compared to Conventional Pesticides
- Product Receives Outstanding Climate Impact Score in Independent Study Product Receives Outstanding Climate Impact Score in Independent Study
- 05/06/2021
|
Marrone Bio leading the charge toward more environmentally-conscious effective pest management for farmers
- Marrone's products are made from naturally-occurring substances like bacteria or plant extracts Biopesticides used in conjunction with chemical ones gives growers more control over pests The biopesticide industry is projected to more than double to $6.4 billion by 2023 What Marrone Bio does: Marrone Bio Innovations Inc (NASDAQ:MBII) is leading the charge toward more environmentally-conscious effective pest management for farmers with its unique line of biological pesticides. Its products are made from naturally occurring substances such as microbes, bacteria, plant extracts, fatty acids or pheromones, and it is currently the only publicly traded biopesticide company on the US market.
- 05/05/2021
|
Marrone Bio Innovations to Report First Quarter 2021 Results on Thursday, May 13th at 4:30 p.m. Eastern Time
- DAVIS, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2021, after market close on Thursday, May 13, 2021 at 4:30 p.m. Eastern time.
- 04/29/2021
|
Marrone Bio Innovations joins United Nations Global Compact, kicks off ESG initiative
- Marrone Bio Innovations Inc (NASDAQ:MBII) announced Monday that it has joined the United Nations (UN) Global Compact, the world's largest corporate sustainability initiative committed to aligning business strategy and operations with universal principles on human rights, labor, environment and anti-corruption. MBI said it has been actively implementing and tracking corporate performance on a number of the UN's sustainable development goals (SDGs) including those around sustainability (water, land, energy and climate change), gender equality and global partnerships.
- 03/29/2021
|
Marrone Bio Innovations Joins United Nations Global Compact & Launches Environmental, Social & Governance Initiative
- Biological Crop Protection Company Leads the Industry with Independent Climate Impact Assessment of Products Biological Crop Protection Company Leads the Industry with Independent Climate Impact Assessment of Products
- 03/29/2021
|
Marrone Bio leading the charge toward more environmentally-conscious effective pest management for farmers
- Marrone's products are made from naturally-occurring substances like bacteria or plant extracts Biopesticides used in conjunction with chemical ones gives growers more control over pests The biopesticide industry is projected to more than double to $6.4 billion by 2023 What Marrone Bio does: Marrone Bio Innovations Inc (NASDAQ:MBII) is leading the charge toward more environmentally-conscious effective pest management for farmers with its unique line of biological pesticides. Its products are made from naturally occurring substances such as microbes, bacteria, plant extracts, fatty acids or pheromones, and it is currently the only publicly traded biopesticide company on the US market.
- 03/25/2021
|
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2020 Results - Earnings Call Transcript
- Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2020 Results - Earnings Call Transcript
- 03/23/2021
|
Marrone Bio Innovations sees its FY2020 revenue climb 31% on its improved product line and international presence
- Marrone Bio Innovations Inc (NASDAQ:MBII) reported a 31% year-over-year surge in its fiscal 2020 revenue to $38.4 million, driven largely by the company's expanded product line and international footprint. Marrone also said its net loss and adjusted EBITDA for the year improved by 46% and 31%, respectively, achieving gross margins of 59.6% as a result of an improved product mix.
- 03/23/2021
|
Marrone Bio Innovations Issues Shareholder Letter
- DAVIS, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released a letter to shareholders from Chief Executive Officer, Kevin Helash.
- 03/23/2021
|
Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2020 Financial Results
- DAVIS, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) has provided its financial results for the fourth quarter and full year ended December 31, 2020. Key results include:
- 03/23/2021
|
MBII Stock Price Increases Over 10% Pre-Market: What You Should Know About The Company
- The stock price of Marrone Bio Innovations Inc (Nasdaq: MBII) has increased by over 10% pre-market. This is what you should know about the company.
- 03/12/2021
|
Marrone Bio Innovations to Report Fourth Quarter and Full Year 2020 Results on Tuesday, March 23rd at 4:30 p.m. Eastern Time
- DAVIS, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the fourth quarter and full year ended December 31, 2020, after market close on Tuesday, March 23, 2021 at 4:30 p.m. Eastern time.
- 03/10/2021
|
Marrone Bio gets boosted $3.50 price target and repeat Buy rating from Canaccord Genuity
- Marrone Bio Innovations Inc (NASDAQ:MBII) (FRA:0MB) shares climbed Friday after an analyst at Canaccord Genuity upped the price target for the company to $3.50 from $2 and reiterated a Buy rating. The company introduced a 2022 revenue projection of $7.7 million based on “a continuing shift to seed and soil treatments and plant health solutions,” with an EBITDA of $1.2 million.
- 02/19/2021
|
Why Marrone Bio Innovations Stock Rose 12% Today
- The bio-agriculture company announced new plans to help fund future growth.
- 02/08/2021
|
Marrone Bio Innovations' New Plant Health Product, Pacesetter®, Delivers a Six to One Return on Investment for Corn and Soybean Farmers
- Marrone Bio Expands into the 179 Million Acre Corn and Soybean Market Marrone Bio Expands into the 179 Million Acre Corn and Soybean Market
- 02/08/2021
|
Marrone Bio Files $90 Million Shelf Registration Statement
- DAVIS, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, announced today it has filed a “universal shelf” registration statement on Form S-3 with the Securities and Exchange Commission (SEC). Under the shelf registration, upon being declared effective by the SEC, Marrone Bio may offer and sell, from time to time over a three-year period, various securities in an amount of up to $90 million.
- 02/08/2021
|
Marrone Bio Innovations Issues Shareholder Letter
- DAVIS, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released a letter to shareholders from Chief Executive Officer, Kevin Helash.
- 02/03/2021
|
Global Adoption of Biologicals Accelerates as Marrone Bio's Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in the U.S.
- DAVIS, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations (NASDAQ: MBII) (MBI), a global provider of bio-based crop protection and plant health products, today announced that it recently received approval for Grandevo WDG Bioinsecticide for use in New Zealand and Chile. Grandevo WDG and Grandevo CG have also been approved for use on hemp by the U.S. Environmental Protection Agency (EPA).
- 01/14/2021
|
Marrone Bio Innovations Announces Effectiveness of Form S-3 Resale Registration Statement
- No Offer of New Securities; Registration Statement Permits Resale of Common Stock from Warrant Financing Exercises No Offer of New Securities; Registration Statement Permits Resale of Common Stock from Warrant Financing Exercises
- 01/05/2021
|
Marrone Bio Provides Update on Warrant Transactions; No New Securities Offered
- DAVIS, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), a leading provider of effective and environmentally responsible pest management and plant health products, today provided an update on its warrant transactions.
- 01/05/2021
|
PGG Wrightson Seeds to Distribute Marrone Bio Innovations' Pro Farm UBP Seed Treatment in Uruguay
- DAVIS, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Farmers in Uruguay will have a new solution to grow a more sustainable crop thanks to a new arrangement that will allow PGG Wrightson Seeds (PGGWS), New Zealand's largest seed company, to distribute Marrone Bio Innovations, Inc.'s (NASDAQ: MBII) (MBI) line of Pro Farm Technology products. The recently signed agreement provides PGGWS with exclusive crop dependent selling rights to MBI's Pro Farm UBP seed treatment line for the next five years (2020-2025) in Uruguay.
- 12/21/2020
|
Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q3 2020 Results - Earnings Call Transcript
- Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Marrone Bio Innovations, Inc. Reports Third-Quarter 2020 Financial Results
- Expansion in international and seed treatment markets led revenue growth and gross margin improvement Expansion in international and seed treatment markets led revenue growth and gross margin improvement
- 11/09/2020
|
Marrone Bio Innovations's Earnings Outlook
- On Monday, November 09, Marrone Bio Innovations (NASDAQ: MBII) will release its latest earnings report. Benzinga's outlook for Marrone Bio Innovations is included in the following report.
- 11/06/2020
|
Marrone Bio Innovations to Report Third Quarter 2020 Results on Monday, November 9th at 4:30 p.m. Eastern Time
- DAVIS, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the third quarter ended September 30, 2020, after market close on Monday, November 9, 2020 at 4:30 p.m. Eastern time.
- 10/26/2020
|
4 Microcaps In The High Mergers And Acquisitions AgTech Space
- The AgTech industry has been undergoing a high degree of M&A, resulting in very few publicly traded AgTech stocks remaining available.
- 10/01/2020
|
Mega Broadband Investments and Cable One Announce Strategic Partnership
- Mega Broadband Investments Holdings LLC (
- 09/28/2020
|
Rizobacter and Marrone Bio Innovations form a Strategic Alliance to Deploy Novel Plant Health and Crop Nutrition Technology in South America
- Rizobacter, a subsidiary of Bioceres Crop Solutions Corp. (NYSE: BIOX) and global leader in sustainable solutions for agriculture, and Marrone Bio Innovations,
- 09/15/2020
|
Marrone Bio Innovations (MBII) Investor Presentation - Slideshow
|
MBII: The addition of pro Farm makes for a blow-out quarter. Biologicals continue to outpace the pesticide industry’s growth rate.
- By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio Innovations (NASDAQ:MBII) reported its second quarter financial results on August 11, 2020 with outstanding gains in revenue and a significant reduction in the net loss. With the inclusion of Pro Farm revenue increased by 74% Y/Y and the net loss dropped from $6.8 million to $2.8 million. This was despite a shift
- 08/12/2020
|
Marrone Bio Innovations, Inc. Reports Second Quarter and First Half 2020 Financial Results
- Second-Quarter Revenue Increased 74% to Record $12.2 Million Record Gross Margins of 60.6% Mark Seventh Consecutive Quarter of 50%+ MarginsDAVIS, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio” or the “Company”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, has provided its financial results for the second quarter ended June 30, 2020.Selected Operating and Financial Highlights $ in millionsQ2 2020Q2 2019% Increase (Decrease)H1 2020H1 2019% Increase (Decrease) Revenues$12.2$7.074%$21.8$15.739% Gross Profit$7.4$3.894%$13.0$8.847% Gross Margin60.6%54.4%+620bps59.3%56.0%+330bps Operating Expenses$9.4$10.2(8%)$20.6$18.99% Operating Expense Ratio77%146%-6,900bps94%120%-2,600bps Net Income (Loss)($2.9)($6.8)(58%)($9.9)($10.7)(7%) Adjusted EBITDA1($1.5)($3.8)(61%)($5.2)($6.4)(18%) Cash Used in Operations($1.5)($3.0)(52%)($7.7)($10.6)(27%) 1Adjusted EBITDA is a non-GAAP financial measure and is described in relation to its most directly comparable GAAP measure under "Use of Non-GAAP Financial Information" below.Second Quarter 2020 Financial Summary * Revenues in the second quarter of 2020 increased 74% to an all-time record of $12.2 million, and the company’s eighth consecutive quarter of year-over-year growth. The increase was driven by global sales in row crops, including Pro Farm’s UBP and Foramin seed treatments. Sales in the specialty crop markets also contributed to the improvement, particularly from the family of Regalia fungicides and Venerate and Grandevo insecticides. * Gross margins in the second quarter of 2020 were 60.6%, the seventh consecutive quarter in which gross margins exceeded 50%. The margin improvement reflected the mix of high-margin foliar and seed treatment products sold in the second quarter. Second quarter 2020 gross profit of $7.4 million was nearly double gross profit of the same period in 2019. * Operating expenses in the second quarter of 2020 decreased 8% to $9.4 million, compared with $10.2 million in the comparable period in 2019. Operating expenses benefited by $1.4 million from a Paycheck Protection Program (PPP) loan secured to retain employees supporting the essential agricultural industry during the COVID-19 pandemic. Spending in the quarter also included the addition of operating expenses from the 2019 acquisition of Pro Farm. * The operating expense ratio – comparing operating expenses to revenues – was 77% in the second quarter of 2020, as compared with 146% in the second quarter of 2019. The ratio improvement quarter-to-quarter reflected significant revenue growth coupled with cost savings efforts and the benefit of the PPP loan. * Net income (loss) in the second quarter of 2020 decreased 58% to a loss of $2.9 million, as compared with a net loss of $6.8 million in the second quarter of 2019. The net loss in the quarter included non-cash adjustments for warrant exercises, stock compensation and the amortization of intangibles related to the Pro Farm acquisition. * Adjusted EBITDA improved by 61%, with a loss of $1.5 million in the second quarter of 2020 as compared with a loss of $3.8 million in the same period last year. Record revenues and gross profit, plus lower operating expenses, drove the improvement in both the net loss and Adjusted EBITDA. Adjusted EBITDA is further described under “Use of Non-GAAP Financial Information” below. * Cash used in operations in the second quarter was $1.5 million, a 52% decline from $3 million in the same period in 2019. Cash used in operations in the quarter included $1.7 million in proceeds from the PPP loan.First Half 2020 Financial Summary * Revenues in the first half of 2020 increased 39% to a record $21.8 million, as compared with $15.7 million in the first half of 2019. The company achieved higher sales in the specialty crop markets, and benefited from its successful BioUnite program with products such as Regalia fungicide and Venerate insecticide. First-half results also grew from sales in the row crop markets, particularly Pro Farm’s UBP and Foramin seed treatments. * Gross profit in the first half rose 47% to $13 million. Gross margins increased by 330 basis points to 59.3%, reflecting product mix. * Operating expenses increased 9% to $20.6 million in the first half of 2020, compared with operating expenses of $18.9 million in the first half of 2019. The increase was driven by the addition of six months of operating expenses from Pro Farm, somewhat offset by the benefit of $1.4 million from the PPP loan. * The operating expense ratio for the first half of 2020 was 94%, a 2,600 basis point improvement that reflected a higher rate of growth for revenues. * Net income (loss) in the first half decreased to a loss of $9.9 million, an improvement over the net loss of $10.7 million in the same period last year. Record revenues and gross profit contributed to the improvement in net loss, somewhat offset by the increase in operating expenses, plus non-cash adjustments related to warrant exercises, stock compensation and amortization charges. * Adjusted EBITDA in the first half of 2020 was a loss of $5.2 million, an 18 percent improvement from an Adjusted EBITDA loss of $6.4 million in the first half of 2019. Adjusted EBITDA is further described under “Use of Non-GAAP Financial Information” below. * Cash used in operations in the first half was $7.7 million, a 27% decline from $10.6 million in the first half of 2019. As in the second quarter, cash used in operations in the first half benefited from $1.7 million in proceeds from the PPP loan.Management Commentary“The second-quarter financial results highlight the momentum our team has created, as well as the opportunity to accelerate our commercial velocity and break out as a market leader,” said Chief Executive Officer Kevin Helash, who joined Marrone Bio effective August 3, 2020. “Our goals to drive profitability are gaining traction as the company transforms itself into a top-tier commercial-scale player in the biological agriculture sector.“This has been a strong start to the year, and it is the foundation from which we can leverage our base business, execute our expansion plans and broaden our global reach. Coupled with a customer-centric culture, and a focus on the execution of our operational and financial objectives, I believe the path to profitability can be accelerated, which will, in turn, create enhanced shareholder value,” added Helash.“We expect to drive continued revenue growth and international expansion in the second half of the year, with gross margins in line with achieving our annual target in the mid-50% range. The integration of the Pro Farm acquisition is going very well, and is tracking to be accretive to net income and cash from operations this year, as we had forecast. While we remain optimistic about the remainder of the fiscal year, plans remain in place for the potential effect that the COVID-19 pandemic may have on macro conditions in the agricultural sector,” Helash concluded.Operational Highlights * Regalia® Maxx biofungicide received the first approval for indoor and outdoor use on cannabis and hemp in Canada, providing farmers an effective new tool to manage difficult diseases, such as botrytis and powdery mildew. * The company entered into a warrant exchange agreement with existing institutional investors, which, assuming exercise in full, is expected to provide adequate cash to reach cash flow breakeven under the company’s current operating plan. The total number of outstanding warrants was reduced by approximately 35%, from 52.6 million to 36.5 million. Expiration dates were significantly shortened ,with new warrants issued in five tranches, expiring by the end of 2021. * Entered into an agreement with Vive Crop Protection to offer a suite of ground-breaking products for U.S. growers that combines the active ingredient in Regalia® with a proven fungicide. The pre-mix product also will contain Vive’s Allosperse Delivery System technology for use in multi applications in major crops, pending regulatory approvals. The company will have rights to directly market a version of the product to specialty crop growers in California.Conference Call and WebcastManagement will host an investor conference call today, August 10, 2020, at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss Marrone Bio Innovations’ 2020 second quarter financial results. The call will conclude with a Q&A from participants. To participate, please use the following information:Q2 2020 Conference Call and Webcast Date: Monday, August 10, 2020 Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time) U.S. Dial-in: 1-866-248-8441 International Dial-in: 1-323-289-6576 Conference ID: 7510516 Webcast: http://public.viavid.com/index.php?id=140993Please dial in at least 10 minutes before the start of the call to ensure timely participation.A playback of the call will be available through September 10, 2020. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally. Please use the replay pin number 7510516. A webcast will also be available for 30 days on the IR section of the Marrone Bio Innovations website or by clicking here: MBII Q2 2020 WebcastAbout Marrone Bio Innovations Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment.
- 08/10/2020
|
SHAREHOLDER ALERT: Purcell Julie and Lefkowitz LLP Is Investigating Marrone Bio Innovations, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
- NEW YORK, NY / ACCESSWIRE / August 10, 2020 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Marrone Bio Innovations, Inc.
- 08/10/2020
|
Earnings Outlook For Marrone Bio Innovations
- Marrone Bio Innovations (NASDAQ: MBII) announces its next round of earnings this Monday, August 10. Here is Benzinga's everything-that-matters guide for this Monday's Q2 earnings announcement.Earnings and Revenue Wall Street analysts see Marrone Bio Innovations reporting a quarterly EPS of $-0.04 per share on sales of $10.38 million. In the same quarter last year, Marrone Bio Innovations posted EPS of $-0.06 on sales of $7.00 million. If the company were to match the consensus estimate when it reports Monday, earnings would be up 33.33%. Revenue would be up 2.67% from the same quarter last year. Here's how the company's EPS has stacked up against analyst estimates in the past:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate -0.03 -0.06 -0.05 -0.04 EPS Actual -0.05 -0.07 -0.05 -0.06 Revenue Estimate 10.11 M 7.34 M 6.95 M 8.33 M Revenue Actual 9.65 M 6.70 M 6.97 M 7.00 M Stock Performance Over the past 52-week period, shares of Marrone Bio Innovations have declined 4.63%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.View more earnings on MBIIDon't be surprised to see the stock move on comments made during its conference call. Marrone Bio Innovations is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://viavid.webcasts.com/starthere.jsp?ei=1348996&tp_key=2053189d5fSee more from Benzinga * Benzinga's Top Upgrades, Downgrades For July 28, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/07/2020
|
Vive Crop Protection and Marrone Bio Innovations form joint agreement
- The fungicide AZterknot FC, slated to receive regulatory approval in mid-2021, is the first product slated from this joint effort.
- 08/06/2020
|
Vive Crop Protection and Marrone Bio Innovations join forces to bring next-generation crop protection solutions to growers
- TORONTO and DAVIS, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, and Vive Crop Protection, a leader in Precision Chemistry solutions and owner of the patented Allosperse® technology, announced an agreement that will provide a suite of ground-breaking products for U.S. growers that combine a leading biological with proven conventional chemistry utilizing the unique Allosperse Delivery System. The first product to come from this joint effort will be AZterknot™ FC, a fungicide for broad crop use marketed by Vive Crop Protection. It fuses the plant health benefits of two actives: Reynoutria extract, the active ingredient in biological market-leader Regalia®, and the disease-fighting power of azoxystrobin, the active ingredient in AZteroid® FC 3.3.AZterknot FC will also contain Vive’s Allosperse Delivery System technology, which provides superior handling characteristics including compatibility with in-furrow, pop-up and foliar liquid fertilizers. Pending EPA registration approval, the product will be approved for foliar and in-furrow application on all major crops in the U.S. (excluding California).Dan Bihlmeyer, vice president of sales and marketing with Vive Crop Protection says, “The collaboration with MBI allows us to bring growers the best of three approaches to crop protection: chemistry, biologicals and nanotechnology. With AZterknot FC, growers will have access to the combined power of a leading biological and of a proven fungicide chemistry. Research has shown that the two actives, in combination with the Allosperse Delivery System, work together to control disease, improve plant health, and increase yield.”MBI will also market a version of the product to specialty crop growers when regulatory approval is granted. Regalia is one of the most used biologicals in the specialty crop market and the combination with azoxystrobin and the Allosperse technology will provide specialty crop growers with the convenience of a single product that delivers enhanced performance and improved yield in a highly compatible formulation.“Our partnership with Vive is an example of how MBI has focused on growth by creating innovative and integrated crop management solutions for growers of a wide range of crops,” said Kevin Hammill, chief commercial officer for Marrone Bio Innovations. “These next-generation BioUnite™ products will not only give U.S. growers access to effective crop protection technology, but it will allow them to better manage their crops by harnessing the power of biologicals with the performance of chemistry.”Regulatory approval for AZterknot FC is expected in mid-2021 and will be available through distributor and retail commercial channels in the U.S.About Vive Crop Protection Vive creates Precision Chemistry to expand the horizons of Precision Ag. Using the Allosperse® Delivery System, Vive greatly improves the targeting and performance of chemical and biological active ingredients, helping growers achieve real results.For more information, visit www.vivecrop.com.About Marrone Bio Innovations Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven®, Pacesetter™, Zelto® Jet Oxide® and Jet Ag® and Zequanox®, with a next-generation insecticide-nematicide, a breakthrough bioherbicide and a biofumigant in the Company’s product pipeline. MBI’s Pro Farm Finland-based subsidiary employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. Products include UBP™ 110, Foramin®, UBP™ Seed Treatment, Foramin® ST.Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.Marrone Bio Innovations Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including, the potential of Regalia pre-mixture with Vive, weather, the novel coronavirus COVID-19, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.Vive Crop Protection Contact: Dan Bihlmeyer, VP Sales and Marketing hello@vivecrop.com 1-810-852-2828Marrone Bio Innovations Contact: Kevin Hammill, Chief Commercial Officer info@marronebio.com 1-530-750-2800Investor Relations Contact: Greg Falesnik or Luke Zimmerman MZ Group – MZ North America Phone: 949-385-6449 MBII@mzgroup.usAZterknotTM, AZteroid® and Allosperse® are trademarks of Vive Crop Protection Inc. Regalia® and all other marks are trademarks of Marrone Bio Innovations
- 08/06/2020
|
Tracking Kahn Brothers Portfolio - Q2 2020 Update
- Kahn Brothers’ 13F portfolio value increased from $547M to $592M this quarter. BP and Patterson-UTI were increased while reducing Hologic and Merck.
- 08/06/2020
|
LD Micro--Announces Preliminary List of Presenters for the LD-500.
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
Marrone Bio Innovations to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th
- Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support
- 08/04/2020
|
Marrone Bio Innovations to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th
- DAVIS, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, announced today that management will present at the Canaccord Genuity 40th Annual Growth Conference. The event is being held virtually and will take place August 11 to 13, 2020. Jim Boyd, Chief Financial Officer, is scheduled to host a virtual presentation during the conference and will also participate in virtual one-on-one meetings throughout the day with Chief Executive Officer Kevin Helash.Canaccord Genuity 40th Annual Growth Conference Date: Wednesday, August 12, 2020 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific Time) Webcast Link: http://wsw.com/webcast/canaccord42/mbii/For more information on the Canaccord Genuity 40th Annual Growth Conference or to schedule a one-on-one meeting, please contact your Canaccord Genuity representative.About Marrone Bio InnovationsMarrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude®, Zelto® Jet Oxide® and Jet Ag® and Zequanox®, with a breakthrough bioherbicide and biofumigant in the Company’s product pipeline. MBI’s Pro Farm Finland-based subsidiary employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. Products include UBP-110®, LumiBio™, LumiBio Valta™, LumiBio Kelta™, Foramin®.Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.Marrone Bio Innovations Forward Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the timing of Helash’s employment and appointment to the company’s board of directors and the company’s goals for future performance. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the Company’s products, weather, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.Investor Relations Contact: Luke Zimmerman Senior Vice President MZ Group – MZ North America 949-259-4987 MBII@mzgroup.us www.mzgroup.us
- 08/04/2020
|
What Type Of Shareholders Make Up Marrone Bio Innovations, Inc.'s (NASDAQ:MBII) Share Registry?
- A look at the shareholders of Marrone Bio Innovations, Inc. (NASDAQ:MBII) can tell us which group is most powerful...
- 07/31/2020
|
Marrone Bio Innovations to Report Second Quarter 2020 Results on Monday, August 10th at 4:30 p.m. Eastern Time
- Company Concurrently Confirms August 3rd Start Date for Incoming Chief Executive Officer and Director Kevin HelashDAVIS, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the second quarter ended June 30, 2020, after market close on Monday, August 10th at 4:30 pm Eastern time. The company also announced that incoming Chief Executive Officer Kevin Helash, a Canadian citizen, has received his visa, and his employment with Marrone Bio and service as a member of its board of directors will commence on August 3, 2020, as anticipated.“I am excited to join the team at Marrone Bio, and look forward to discussing the second quarter financial results with our shareholders on the August 10th conference call,” said Helash.Management will host an investor conference call at 1:30 p.m. PT (4:30 p.m. ET) on August 10, 2020 to discuss Marrone Bio Innovations’ second quarter 2020 financial results, provide a corporate update, and conclude with a Q&A from participants. To participate, please use the following information:Q2 2020 Conference Call and Webcast Date: Monday, August 10th, 2020 Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time) U.S. Dial-in: 1-866-248-8441 International Dial-in: 1-323-289-6576 Conference ID: 7510516 Webcast: http://public.viavid.com/index.php?id=140993Please dial in at least 10 minutes before the start of the call to ensure timely participation.A playback of the call will be available through September 10, 2020. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally. Please use the replay pin number 7510516. A webcast will also be available for 30 days on the IR section of the Marrone Bio Innovations website or by clicking here: MBII Q2 2020 Webcast.About Marrone Bio InnovationsMarrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude®, Zelto® Jet Oxide® and Jet Ag® and Zequanox®, with a breakthrough bioherbicide and biofumigant in the Company’s product pipeline. MBI’s Pro Farm Finland-based subsidiary employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. Products include UBP-110®, LumiBio™, LumiBio Valta™, LumiBio Kelta™, Foramin®.Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.Marrone Bio Innovations Forward Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the timing of Helash’s employment and appointment to the company’s board of directors and the company’s goals for future performance. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the Company’s products, weather, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.Investor Relations Contact: Greg Falesnik or Luke Zimmerman MZ Group – MZ North America Phone: 949-385-6449 MBII@mzgroup.us
- 07/24/2020
|
Ipoh to become cleanest city in Malaysia by 2023 — Mayor
- IPOH (July 18): Ipoh City Council (MBI) aims to make Ipoh the cleanest city in Malaysia by 2023, said its mayor Datuk Rumaizi Baharin (pictured). He said the city council has carried out numerous efforts including upgrading assets and increasing maintenance staff, especially to carry out sanitation works. “These assets include lorries, trucks and other vehicles. We need to replace these as they already reached 10 to 15 years of service. I think these assets are old and if we don’t replace them we will have trouble in carrying out our work.
- 07/18/2020
|
McKay Brothers führt Bandbreite mit niedrigster bekannter Latenz für
Verbindungen Illinois - Busan und Tokio - Busan ein
- McKay Brothers International (MBI) hat eine Erweiterung seiner privaten Bandbreitendienste mit der niedrigsten bekannten Latenz auf Busan bekannt gegeben.
- 07/13/2020
|
Marrone Bio Appoints Kevin Helash as Chief Executive Officer
- Marrone Bio Innovations, Inc., (MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to global agricultural needs, today announced the appointment of Kevin Helash as its new chief executive officer. Concurrent with joining the company, he will be appointed to serve as a member of the board of directors. Helash, 55, a native of Manitoba, Canada, will join the company as early as August 1, 2020.
- 07/06/2020
|
BSNL cancels 4G tender after DoT directs it not to use Chinese telecom gear
|
Global Herbicides Market By Type, By Mode of Action, By Crop Type, By Company, By Region, Forecast & Opportunities, 2025
- This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. Global Herbicides Market By Type (Glyphosate; Diquat; 2,4-Dichlorophenoxyacetic acid; and Others), By Mode of Action (Selective Vs.
- 06/27/2020
|
MBII: Regalia, Marrone Bio’s most successful product, is the number one biofungicide in California, and is now available on Amazon.
- By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio (NASDAQ:MBII) has announced that Regalia is the leading biofungicide in California, with a market share of over 25% in the leaf biofungicide treatment market, for the January 2020 through April 2020 growing season. Despite a 12.8% increase in acres treated by biofungicides overall organic and chemical treatment
- 06/26/2020
|
Marrone Bio Innovations’ Regalia® is Top Biofungicide Brand in California
- DAVIS, Calif., June 24, 2020 -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today.
- 06/24/2020
|
Jio poised to play key role in development of 5G ecosystem in India: RIL
|
Jio Platforms' bull-case value seen at USD 110 bn by FY22 on ARPU growth: BofA Securities
|
Telcos raise watch over systems amid govt warning of phishing attacks using COVID-19 as bait
|
Fitch revises outlook on Airtel to negative from stable; affirms at 'BBB-'
|
Marrone Bio Innovations Regains Compliance with Nasdaq Minimum Bid Price Requirement
- DAVIS, Calif., June 22, 2020 -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today.
- 06/22/2020
|
COVID-19 crisis: Airtel to pay May salaries of 30K staff employed by retail, distribution partners
|
AIIMS study observes Mild Behavioural Impairment as precursor of Dementia
- The study named `Behavioural issues in late life may be the precursor of dementia - A cross-sectional evidence from memory clinic of AIIMS, India` conducted by the Department of Geriatric medicine also stressed on multimorbidity, diabetes and urinary incontinence to be significantly associated with MBI.
- 06/18/2020
|
Corporate decisions separate from geopolitical issues, says COAI amid India-China standoff
|
Ormas keagamaan apresiasi pemerintah tunda pembahasan RUU HIP
- Para pimpinan organisasi keagamaan mengapresiasi keputusan pemerintah yang menunda pembahasan Rancangan Undang-Undang Haluan Ideologi Pancasila (RUU ...
- 06/17/2020
|
White Mississippi cop's case files released shooting dead a black man
- Officer Canyon Boykin fatally shot 26-year-old Ricky Ball following the chase in Columbus, Mississippi, back in October 2015.
- 06/16/2020
|
Assured Guaranty's Current Price Reflects Far Too Pessimistic Of A Future (NYSE:AGO)
- AGO trades at around 26% of adjusted book value per share, which is likely to keep growing. The company entered the Covid-19 crisis in the strongest financial p
- 06/15/2020
|
Reliance raises Rs 1.04 lakh cr from marquee investors in 8 weeks
|
TPG, L Catterton pick up 1.32% stake in Jio Platforms for Rs 6441.3 crore
|
Edited Transcript of MBII earnings conference call or presentation 11-May-20 8:30pm GMT
- Q1 2020 Marrone Bio Innovations Inc Earnings Call
- 06/11/2020
|
MBII: Marrone Bio signs exclusive agreement with UPL to use REGALIA MAXX in the Republic of South Africa.
- By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio Innovations, Inc. (NASDAQ:MBII) has signed an exclusive agreement with UPL to distribute REGALIA MAXX in the Republic of South Africa, the country on the most southern point of South Africa. Following the acquisition of Arysta Life Science in February, 2019 UPL became the fifth largest agricultural solutions
- 06/10/2020
|
MBIA Inc. (NYSE:MBI) Holdings Reduced by Swiss National Bank
- Swiss National Bank cut its stake in MBIA Inc. (NYSE:MBI) by 4.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,500 shares of the insurance provider’s stock after selling 6,700 shares during the period. Swiss National Bank’s holdings in MBIA […]
- 06/10/2020
|
Marrone Bio Innovations Reports Exclusive Distribution Deal With UPL For REGALIA MAXX In Republic Of South Africa
|
Marrone Bio Innovations and UPL Sign Exclusive Distribution Agreement for REGALIA® MAXX in the Republic of South Africa
- DAVIS, Calif., June 09, 2020 -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today.
- 06/09/2020
|
Cannabis Stock Gainers And Losers From June 8, 2020
|
Marrone Bio Innovations announces Pacesetter
- Marrone Bio Innovations Inc., Davis, California, a leader in sustainable bioprotection and plant health solutions, has announced that Pacesetter, a recently approved bio-based plant health product, is now available to
- 06/08/2020
|
Dropping case of white ex-cop a 'knife' to trust, rep says
- JACKSON, Miss. (AP) — A Mississippi lawmaker on Thursday criticized the state attorney general's decision to drop the prosecution of a white former police officer who was indicted in the 2015...
- 06/04/2020
|
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
- NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from around ...
- 06/03/2020
|
Hedge Funds Warming Up To Marrone Bio Innovations Inc (MBII)
- The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
- 05/29/2020
|
Covid-19 crisis and India’s next government
- The Covid crisis has politicised a new crop of leaders who are young, smart, and committed to the country
- 05/29/2020
|
Cannabis Stock Gainers And Losers From May 28, 2020
|
Marrone Bio Innovations to Present at the June 2020 Virtual Investor Summit
- DAVIS, Calif., May 26, 2020 -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today.
- 05/26/2020
|
Karla Medina-Ortega Joins Certis USA as Regional Field Development Manager
- Certis USA, the leader in biopesticides, today announced its hiring of Dr. Karla Medina-Ortega as Field Development Manager for Southern USA.
- 05/26/2020
|
Global Bio-herbicides Market Analysis and Outlook 2020-2028 - ResearchAndMarkets.com
|
MBII: Marrone now covers two of the largest areas of organic cannabis cultivation in N. America.
- By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio Innovations (NASDAQ:MBII) has announced that it has received the first approval of the use of REGALIA MAXX biofungicide for the use on cannabis and hemp (hemp and marijuana are two varieties of the same plant cannabis sativa) in Canada. Cannabis is susceptible to powdery mildew. It can destroy complete crops and
- 05/15/2020
|
Aegis Capital Maintains Buy on Marrone Bio Innovations, Lowers Price Target to $1.4
|
Marrone Bio Innovations' REGALIA MAXX Receives First Approval For Use On Cannabis And Hemp In Canada
|
Marrone Bio Innovations’ REGALIA® MAXX Receives First Approval for Use on Cannabis and Hemp in Canada
- Marrone Bio Innovations, Inc. (MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, announced today that REGALIA® MAXX biofungicide received the first approval for indoor and outdoor use on cannabis and hemp in Canada. Cannabis and hemp have been relatively small crops in Canada until lifestyle cannabis was approved in 2018. According to Health Canada, 77,800 acres of hemp were grown in 2018, valued at an estimated $50 million USD.
- 05/14/2020
|
Tracking Kahn Brothers Portfolio - Q1 2020 Update
- Kahn Brothers’ 13F portfolio value decreased from $825M to $547M this quarter. The New York Times position was almost sold out during the quarter. The portfolio
- 05/14/2020
|
Marrone Bio Innovations' REGALIA® MAXX Receives First Approval for Use on Cannabis and Hemp ...
|
Cannabis Stock Gainers And Losers From May 13, 2020
|
Worldwide Biopesticide Competitive Analysis and Leadership Study 2018 - ResearchAndMarkets.com
|
MBII: Marrone reported record revenue and record gross margins in the first quarter. The company expects year over year growth to exceed the 39% achieved in 2019.
- By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio Innovations (NASDAQ:MBII) reported record revenue and a further increase in gross margins in the first quarter of 2020. Costs were impacted by the addition of Pro Farm which did not make a significant impact on revenue. Both Regalia and Venerate were strong contributors during the quarter. COVID-19 did not have a
- 05/12/2020
|
Marrone Bio Innovations, Inc. (MBII) Pam Marrone on Q1 2020 Results - Earnings Call Transcript
- Marrone Bio Innovations, Inc. (NASDAQ:MBII) Q1 2020 Earnings Conference Call May 11, 2020, 04:30 PM ET Company Participants Linda Moore - General Counsel Jim Bo
- 05/12/2020
|
Marrone Bio Innovations Q1 EPS $(0.050) Misses $(0.030) Estimate, Sales $9.650M Miss $10.110M Estimate
|
Marrone Bio Innovations, Inc. Reports First Quarter 2020 Financial Results
- Record Revenues; Seventh Consecutive Quarter of Year Over Year Revenue Growth Realized in Challenging Environment for Agricultural Production Record Gross Margins Mark Sixth.
- 05/11/2020
|
MBIA Inc. Reports First Quarter 2020 Financial Results
- MBIA Inc. (NYSE:MBI) today posted its first quarter 2020 financial results on its website at https://investor.mbia.com/investor-relations/financial-in
- 05/11/2020
|
Flower and Ornamental Plants Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2026
- May 06, 2020 (The Expresswire) --
Global “Flower and Ornamental Plants Market ” analysis 2020 covers the entire supply chain, focusing on supply, demand,...
- 05/07/2020
|
Cannabis Stock Gainers And Losers From May 6, 2020
|
Cannabis Stock Gainers And Losers From May 5, 2020
|
ESPAÑOL • Noticias del Día: Una Línea de Ropa de 'Narcos', Alice Moon y el SHC, Acciones de Cannabis, MindMed y el LSD, y Más
- Las últimas noticias sobre cannabis, cáñamo, CBD, psicodélicos, y otras temáticas verdes, ahora en Benzinga en Español, vía El...
- 05/05/2020
|
MBII: Restructured capitalization of warrants reduces potential dilution. Marrone Bio reaffirms path to positive cash flow.
- By Ian Gilson, PhD, CFA NASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Following the recent Form S-1 registration of stock and warrants (outlined below), the major stockholders and Marrone Bio Innovations (NASDAQ:MBII) have signed a warrant exchange agreement. Under the agreement 46 million existing warrants will be swapped for 29.9 million new warrants with various expiration dates and an
- 05/04/2020
|
MBII: Restructured capitalization of warrants reduces potential dilution. Marrone Bio reaffirms path to positive cash flow.
|
Ombudsman minta Gubernur Sumut evaluasi Tim Gugus Tugas COVID-19
- Kepala Ombudsman RI Perwakilan Sumut Abyadi Siregar meminta gubernur setempat, Edy Rahmayadi mengevaluasi Tim Gugus Tugas karena kasus mogoknya tenaga medis ...
- 05/03/2020
|
Marrone Bio Innovations to Report First Quarter 2020 Results on Monday, May 11th at 4:30 p.m. Eastern Time
- DAVIS, Calif., May 01, 2020 -- Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, will release.
- 05/01/2020
|
Marrone Bio Announces Warrant Exchange Agreement
- Marrone Bio Innovations, Inc. (MBII) (the “Company” or “Marrone Bio”) an international leader in sustainable bioprotection and plant health solutions, has signed a warrant exchange agreement with existing institutional investors that immediately reduces the total number of outstanding warrants by approximately
- 04/30/2020
|
Cannabis Stock Gainers And Losers From April 30, 2020
|
Cannabis Stock Gainers And Losers From April 28, 2020
- Gainers
Nextleaf Solutions (OTC: OILFF) shares closed up 27.5% at $0.26
Greenlane Holdings (NASDAQ: GNLN) shares closed up 13.45% at $3.29
Harvest Health (OTC:...
- 04/28/2020
|
Marrone Bio Innovations Receives Nasdaq Notice Regarding Failure to Satisfy a Continued Listing Rule
- Marrone Bio Innovations, Inc. (MBII) (the “Company”) today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) as a result of the company’s closing bid price being below $1.00 per share for 30 consecutive days. Under Nasdaq Listing Rules, the Company usually has 180 calendar days from the date of the notification to regain compliance with Nasdaq Listing Rules.
- 04/24/2020
|
Marrone Bio Innovations Receives Nasdaq Notice Regarding Failure to Satisfy a Continued Listing Rule
|
Cannabis Stock Gainers And Losers From April 22, 2020
- Gainers
Body and Mind (OTC: BMMJ) shares closed up 26.55% at $0.48
Bloom Energy (NYSE: BE) shares closed up 17.13% at $7.93
Cann Group (OTC: CNGGF) shares closed...
- 04/22/2020
|
Publicly Traded Companies Got $300 Million In Small Business Loans: AP Investigation
- Neither the Trump administration nor the lending industry has disclosed a list of Paycheck Protection Program beneficiaries.
- 04/21/2020
|
AP: Publicly traded firms get $300M in small-business loans
- The Paycheck Protection Program was supposed to infuse small businesses with $349 billion in emergency loans that could help keep workers on the job and bills paid on time. But at least 75 companies that received the aid were publicly traded.
- 04/21/2020
|
Wave Life Sciences among public companies given small-business loan, AP reports WVE;LIND;QMCO;BWEN;MBII;HSDT;ENSV
- Wave Life Sciences among public companies given small-business loan, AP reports WVE LIND QMCO BWEN MBII HSDT ENSV
- 04/21/2020
|
AP: Publicly traded firms get $300M in small-business loans
- Companies with thousands of employees, past penalties from government investigations and risks of financial failure even before the coronavirus walloped the economy were among those receiving millions of dollars from a relief fund that Congress created to help small businesses through the crisis, an Associated Press investigation found. The Paycheck Protection Program was supposed to infuse small businesses, which typically have less access to quick cash and credit, with $349 billion in emergency loans that could help keep workers on the job and bills paid on time. But at least 75 companies that received the aid were publicly traded, the AP found, and some had market values well over $100 million. And 25% of the companies had warned investors months ago — while the economy was humming along — that their ability to remain viable was in question. By combing through thousands of regulatory filings, the AP identified the 75 companies as recipients of a combined $300 million in low-interest, taxpayer-backed loans. Eight companies, or their subsidiaries, received the maximum $10 million possible, including a California software company that settled a Securities and Exchange Commission investigation late last year into accounting errors that overstated its revenue. The eight firms getting maximum loans are likely just a tip of the iceberg: Statistics released last week by the U.S. Small Business Administration showed that 4,400 of the approved loans exceeded $5 million. Overall, the size of the typical loan nationally was $206,000, according to the statistics. SBA will forgive the loans if companies meet certain benchmarks, such as keeping employees on payroll for eight weeks. The list of recipients identified by the AP is a fraction of the 1.6 million loans that lenders approved before the program was depleted last...
- 04/21/2020
|
AP: Publicly traded firms get $300M in small-business loans
- Companies with thousands of employees, past penalties from government investigations and risks of financial failure even before the coronavirus walloped the economy were among those receiving millions of dollars from a relief fund that Congress created to help small businesses...
- 04/21/2020
|
AP: Publicly traded firms get $300M in small-business loans
- Companies with thousands of employees, past penalties from government investigations and risks of financial failure even before the coronavirus walloped the economy were among those receiving millions of dollars from a relief fund that Congress created to help small businesses through the crisis, an
- 04/21/2020
|
Ketua MPR berikan bantuan pada keluarga terdampak COVID-19
- Ketua Majelis Permusyawaratan Rakyat (MPR) RI Bambang Soesatyo bersama organisasi kemasyarakatan Gerakan Keadilan Bangun Solidaritas (GERAK BS) dan Motor ...
- 04/20/2020
|
Marrone Bio gets $1.7 million PPP loan
- Davis-based Marrone Bio Innovations Inc. received $1.7 million in funding under the Paycheck Protection Program, the federal government's main initiative to help small businesses disrupted by the COVID-19 pandemic.
- 04/17/2020
|
Marrone Bio Innovations Provides Corporate Update
- Marrone Bio Innovations Inc. (MBII) (the “Company” or “Marrone Bio”), an international leader in sustainable bioprotection and plant health solutions, today provided a corporate update on recent corporate governance and operational initiatives. In December 2019, Marrone Bio’s Board of Directors announced that the Company’s founder, Dr. Pamela Marrone, would retire from her position as chief executive officer. At that time, the Board of Directors initiated a search process for a new CEO, and subsequently have identified a final candidate for consideration.
- 04/17/2020
|
Marrone Bio Innovations Secures $1.7 Million Loan Under Paycheck Protection Program Provision of CARES Act
- Marrone Bio Innovations Inc. (MBII) (the “Company” or “Marrone Bio”), an international leader in sustainable bioprotection and plant health solutions, has secured a $1.7 million loan under the Paycheck Protection Program (PPP) (the “Loan”) contained within the Coronavirus Aid, Relief and Economic Security (CARES) Act that was signed into law on March 27, 2020. As a U.S. small business, Marrone Bio qualified for the PPP, which allows businesses and nonprofits with fewer than 500 employees to obtain loans of up to $10 million to incent companies to maintain their workers as they manage the business disruptions caused by the COVID-19 pandemic.
- 04/17/2020
|
Marrone Bio Reports Secures $1.7M Loan Under Paycheck Protection Program
|
Marrone Bio Innovations to Attend SNN Planet MicroCap Showcase 2020 Virtual Investor Conference
- DAVIS, Calif., April 14, 2020 -- Marrone Bio Innovations Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, today announced.
- 04/14/2020
|
Here's What We Think About Marrone Bio Innovations, Inc.'s (NASDAQ:MBII) CEO Pay
- Pam Marrone became the CEO of Marrone Bio Innovations, Inc. (NASDAQ:MBII) in 2006. First, this article will compare...
- 04/13/2020
|
MBII: Marrone's new product, Pacesetter, receives EPA approval. Trials on corn, soybeans and wheat show high returns on investment.
|
Marrone Bio Announces Introduction of New Synergistic Plant Health Product Available to Corn, Soybean and Wheat Growers
- Marrone Bio Innovations Inc. (MBII), an international leader in sustainable bioprotection and plant health solutions, today announced that Pacesetter™, a recently approved bio-based plant health product, is now available to corn, soybean and wheat growers in the United States. Pacesetter acts synergistically with conventional fungicides to improve plant health and vigor, increasing yield by up to seven bushels per acre in soybeans and 13 bushels per acre in corn.
- 04/07/2020
|
Marrone Bio Innovations Reports Its Pacesetter Bio-Based Plant Health Product Is No Available To Corn, Soybean, Wheat Growers In US
|
Edited Transcript of MBII earnings conference call or presentation 12-Mar-20 8:30pm GMT
- Q4 2019 Marrone Bio Innovations Inc Earnings Call
- 03/31/2020
|
Marrone Bio Innovations Highlights Form S-1 Resale Registration For Common Stock By Certain Shareholders, No Terms Disclosed
|
Cannabis Stock Gainers And Losers From March 27, 2020
- Gainers
Aurora Cannabis (NYSE: ACB) shares closed up 15.44% at $1.04
Tilray (NASDAQ: TLRY) shares closed up 15.19% at $9.10
Curaleaf Holdings (OTC: CURLF) shares...
- 03/27/2020
|
The market studied was valued at USD 1,347.6 million in 2019 registering a CAGR of 5.8%, during the forecast period (2020-2025
- During the study period, it has been found that although the advent of bio-based nematicides is registering a high growth rate in terms of development and adoption, the chemical nematicides segment still occupies the largest share in the overall market. The rate of application of Halogen compounds and
- 03/24/2020
|
MBII: Marrone receives EPA approval for killing Coronaviruses on hard surfaces in the food industries.
|
Marrone Bio Reports Its Jet-Oxide 15% Sanitizer Product Is Allowed By US EPA For Use On Industrial Hard Surfaces For Human Coronaviruses
|
Global Nematicides Market Outlook, 2025 - Bio-Based Nematicides Present Lucrative Growth Potential
- The "Nematicides Market - Growth, Trends and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
- 03/19/2020
|
Global Nematicides Market: Growth, Trends and Forecast (2020-2025)
- Dublin, March 18, 2020 -- The "Nematicides Market - Growth, Trends and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering..
- 03/18/2020
|
Cannabis Stock Gainers And Losers From March 17, 2020
- Gainers Australis Capital (OTC: AUSAF ) shares closed up 37.48% at $0.14 Marrone Bio Innovations (NASDAQ: MBII ) shares closed up 22.79% at $0.88 Corbus Pharmaceuticals (NADAQ: CRBP) shares closed up 22.38% at $4.21 22nd Century Group, Inc. Common Stock (AMEX: XXII) shares closed up 17.77% at $0.78 Meridian Bioscience (NASDAQ: VIVO ) shares closed up 16.85% at $7.49 Green Thumb Industries (OTC: GTBIF ) … Full story available on Benzinga.com
- 03/17/2020
|
MBII: Marrone Bio Innovations reported 2019 year end data. Gross margins continue to improve. The company expects revenue growth in 2020 to be above that of 2019.
|
Earnings Scheduled For March 12, 2020
- Companies Reporting Before The Bell Dollar General Corporation (NYSE: DG ) is projected to report quarterly earnings at $2.02 per share on revenue of $7.15 billion. Genesco Inc. (NYSE: GCO ) is estimated to report quarterly earnings at $2.75 per share on revenue of $680.43 million. BEST Inc. (NYSE: BEST ) is expected to report quarterly earnings at $0.42 per share on revenue of $10.90 billion. 58.com Inc. (NYSE: WUBA ) is projected to report quarterly earnings at $0.80 per share on revenue of $587.26 million. Genesis Healthcare, Inc. (NYSE: GEN ) is estimated to report quarterly loss at $0.11 per share on revenue of $1.09 billion. Spartan Motors, Inc. (NASDAQ: SPAR ) is expected to report quarterly earnings at $0.36 per share on revenue of $230.00 million. Party City Holdco Inc. (NYSE: PRTY ) is estimated to report quarterly earnings at $0.88 per share on revenue of $748.82 million. RadNet, Inc. (NASDAQ: RDNT ) is projected to report quarterly earnings at $0.15 per share on revenue of $294.16 million.
- 03/12/2020
|
Marrone Bio Innovations FY19 EPS $(0.32) Down From $(0.2) YoY, Sales $29.373M Up From $21.22M YoY
|
Marrone Bio Innovations Signs Commercial Agreement with Anasac Chile S.A. ...
|
Cannabis Stock Gainers And Losers From March, 4. 2020
- Gainers
Cronos Group (NASDAQ: CRON) shares gained 12.03%, to close at $5.96. Follow the latest news about Cronos.
Lovesac (NASDAQ: LOVE) shares rose 11.83%,...
- 03/04/2020
|
Global Fungicides Market Insights, 2015-2030 - Rapid Population Growth, Depleting Cultivable Land, Lack of Proper Regulations
- The "Fungicides Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.
- 03/03/2020
|
Fruit and Vegetable-Rich Diet Key to Avoiding Gestational Diabetes
- Gestational diabetes is a condition that afflicts women during pregnancy who did not have diabetes before becoming pregnant. GDM typically onsets around the middle of the pregnancy term, between 24 and 28 weeks, and can recur during subsequent pregnancies.
- 02/27/2020
|
50 pekerja Black Owl terancam PHK akibat pencabutan izin
- Manajemen Restoran dan Pub Black Owl Efrat Tio menyatakan sebanyak 50-an pekerja terancam pemutusan hubungan kerja (PHK) akibat pencabutan izin usaha yang ...
- 02/17/2020
|
Marrone Bio Innovations to Attend the Bank of America Global Agriculture and Materials ...
|
Analysts: These 3 Penny Stocks Are Positioned for Big Gains in 2020
- Penny stocks, you either love them or you hate them. One of the obvious draws of these stocks trading for under $5 per share is the ability to get more bang for your buck. And should these bargain priced stocks see their share prices rise by only a small amount, the rewards can be staggering.However,
- 02/12/2020
|
Analysts: These 3 Penny Stocks Are Positioned for Big Gains in 2020
- Penny stocks, you either love them or you hate them. One of the obvious draws of these stocks trading for under $5 per share is the ability to get more
- 02/12/2020
|
Global Fungicides Market Report (2020 to 2023) - CAGR of 11% Expected During the Forecast Period - ResearchAndMarkets.com
- The "Fungicides Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.
- 02/12/2020
|
5 Agricultural Inputs Stocks Moving In Friday's Session
|
30 Basic Materials Stocks Moving In Tuesday's Session
|
MBII: Stargus receives California approval. Marrone Bio Innovations extends registration applications.
|
Marrone Bio Announces Approval Of Stargus Biofungicide In California
|
MBII: Marrone Bio Innovations adds to credit facility based on short term assets. Our estimates do not include any financials from the recent acquisitions.
|
Marrone Bio Innovations Announces New $23M Accounts-Receivable And Inventory-Backed Credit Facilities
|
MBII: Marrone Bio Innovations pursuing state approvals for biopesticides on the hemp variety of cannabis.
|
Mid-Morning Market Update: Markets Mixed; Pier 1 Imports Posts Wider Q3 Loss
|
Marrone Bio Innovations Announces US EPA Approval Of Regalia And Stargus For Hemp
|
Two Marrone Bio Products Appear On EPA Site Of Approved Hemp Pesticides
|
MBII: Marrone Bio Innovations announces the results of a next generation nematicide/insecticide, MBI-306.
|
Marrone Announces Results Of US Field Trial Of Its Nematicide/Insecticide Demonstrating ' Improved Levels of Crop Protection and Yield'
|
Burnout Is About Your Workplace, Not Your People
- Leaders create the conditions that lead to burnout — or prevent it.
- 12/11/2019
|
MBII: Marrone Bio Innovations reports results of nematode control on corn and improved stress tolerance on barley and wheat.
|
Marrone Bio Says Results Of 2019 Field Trials For Biology-Based Seed Treatments Demonstrated 'improved yields and cost-effective control of soil insects and nematodes that are equivalent to or better than current industry standards'
|
Marrone Bio Innovations's CEO announces retirement
|
Marrone Bio Innovations Announces Plans for CEO Succession
|
Stocks That Hit 52-Week Lows On Wednesday
|
Small firms are a part of the big picture in innovation
- X-ray technology firm Micro-X proves that small firms can punch above their weight in the collaborative effort to build defence capability.
- 11/26/2019
|
Stocks That Hit 52-Week Lows On Thursday
|
Micro-X hones in on equity raising
- Stockbroker Morgans is expected to close the books on an equity raising for lightweight X-ray products maker Micro-X.
- 11/17/2019
|
Marrone Bio Innovations, Inc. (MBII) CEO Pam Marrone on Q3 2019 Results - Earnings Call Transcript
|
Marrone’s New Bioherbicide Shows Promise in Palmer Amaranth Fight
- Marrone Bio Innovations has discovered positive results in 2019 field trials for its new bioherbicide, MBI-015.
- 11/12/2019
|
Marrone Bio Innovations Q3 EPS $(0.14) Misses $(0.05) Estimate, Sales $6.966M Beat $6.95M Estimate
|
Marrone Bio Innovations Announces Approval Of Stargu In Mexico
|
Marrone Bio Acquires Jet Ag And Jet Oxide Product Lines
|
Cannabis Stocks Gainers and Losers From September 9
|
Fairpointe Capital LLC Buys Agilent Technologies Inc, Magna International Inc, iShares MSCI ...
|
Marrone Bio Innovations' (MBII) CEO Pam Marrone on Q2 2019 Results - Earnings Call Transcript
|
Marrone Bio Innovations Q2 EPS $(0.06) Misses $(0.04) Estimate, Sales $6.997M Miss $8.33M Estimate
|
Marrone Bio Innovations to Report Second Quarter —…–9 Results on Thursday, August 8th at ...
|
Marrone Bio Innovations And Valagro Announce Research Collaboration
|
Marrone Bio Innovations Receives Notice Of Allowance OF Claims From US Patent Office
|
Companies Which Will Be Presenting At LD Micro's 9th Annual Micro Invitational Tues., Jun. 4, 2019
|
Marrone Bio Innovations to Present at the 9th Annual LD Micro Invitational Investor Conference ...
|
Compass Minerals' Plant Nutrition Unit, Marrone Bio Innovations Report Collaboration To Develop New Specialty Plant Nutrient Products Enhanced With Microorganisms
|
Marrone Bio Innovations, Inc. (MBII) CEO Pamela Marrone on Q1 2019 Results - Earnings Call Transcript
|
Marrone Bio Innovations, Inc. - Common Stock Q1 EPS $(0.04), Inline, Sales $8.601M Beat $6.46M Estimate
|
33 Stocks Moving In Wednesday's Mid-Day Session
|
Marrone Bio Innovations shares are trading higher after the company announced Regalia Maxx received label approval from Canada's Pest Management Regulatory Agency.
|
World of Modular 2019 Conference a Record-Setting Success | STL.News
- World of Modular 2019 Conference a Record-Setting Success | STL.News
- 04/01/2019
|
Smartsel keeps an eye on Selangor citizens’ pain points
- We are looking at how to help the state improve the availability, speed and affordability of digital communications infrastructure, says CEO
By HABHAJAN SINGH A Selangor entity is pushing hard to assist the state to navigate the wave of smart city transformation, as well as dealing with the Internet of Things and big data. Smartsel Sdn Bhd, a wholly owned […]
- 03/15/2019
|
Marrone Bio Reports Q4 Earnings, Plans To Prioritize Cannabis Market
|
Marrone Bio beats on revenue
|
Marrone Bio Innovations Granted USPTO Claims For MBI-110 Bacterium, Active Ingredient In Amplitude And Stargus Biofungicides
|
Marrone Bio Innovations CEO Pam Marrone to receive 'Sustie' award for her contributions to ...
|
Marrone Bio Innovations Announces Its MBI-110 Biofungicide And Haven Sunprotectant Products Have Received Approval For Sale In Canada
|
12 NYSE- And NASDAQ-Listed Stocks With Cannabis Exposure
|
MARRONE BIO (MBII) Investor Presentation - Slideshow
|
Marrone Bio Innovations, Inc. - Common Stock Q3 EPS $(0.04) Up From $(0.27) YoY, Sales $5.425M Miss $7.17M Estimate
|
Marrone Bio Innovations Reports Int'l. Distribution Deal With Agricultural Materials Co. In Turkey, No Terms Disclosed
|
Marrone Bio Innovations Pest Management Products Win the International Biocontrol Manufacturers ...
|
Marrone Bio Innovations Appoints Barner Jones as New Director of National Sales and Account ...
|
Exit strategy: five options which could work for your business
- When it comes to choosing the right exit strategy for your business, it is important to weigh up all your options. Here are five.
- 09/26/2018
|
Marrone Bio Innovations Announces Distribution Partnership With Hop Tri Investment Corporation In Vietnam; Hop Tri Plans To Register And commercialize MBI's GRANDEVO Bioinsecticide And REGALIA Biofungicide
|
Marrone Bio Innovations Has Bought Itself Some Time, But Not Much
|
Marrone Bio Innovations Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $5.72M Miss $7.01M Estimate
|
Marrone Bio Innovations Submits Novel Bioherbicide to the EPA for Regulatory Approval
|
